Mol Cell Biol 2003, 23:5867–5881.PubMedCrossRef

30. Khan S, Abdelrahim M, Samudio I, Safe S: Estrogen receptor/Sp1 complexes are required for induction of cad gene expression by 17beta-estradiol in this website breast cancer cells. Endocrinology 2003, 144:2325–2335.PubMedCrossRef 31. Schultz JR, Petz LN, Nardulli AM: Cell- and ligand-specific regulation of promoters containing activator protein-1 and Sp1 sites by estrogen receptors alpha and beta. J Biol Chem 2005, 280:347–354.PubMed 32. Safe S: Transcriptional activation of genes by 17 beta-estradiol through estrogen receptor-Sp1 interactions. Vitam Horm 2001, 62:231–252.PubMedCrossRef 33. Lind H, Zienolddiny S, Ekstrom PO, Skaug V, Haugen AZD5363 A: Association of a functional polymorphism in the promoter of the MDM2 gene with risk of nonsmall cell lung cancer. Int J Cancer 2006, 119:718–721.PubMedCrossRef 34. Mitchell AA, Cutler DJ, Chakravarti A: Undetected genotyping errors cause apparent overtransmission of common alleles in the transmission/disequilibrium test. Am J Hum Genet 2003, 72:598–610.PubMedCrossRef 35. Hosking L, Lumsden S, Lewis K, Yeo A, McCarthy L, Bansal A, et al.: Detection of genotyping errors by Hardy-Weinberg equilibrium testing. Eur J Hum Genet 2004, 12:395–399.PubMedCrossRef 36. Salanti G, Amountza G, Ntzani EE, Ioannidis JP: Hardy-Weinberg equilibrium in genetic association studies: an empirical evaluation of reporting, deviations,

and power. Eur J Hum Genet 2005, 13:840–848.PubMedCrossRef 37. Trikalinos TA, Salanti G, Proton pump modulator Khoury MJ, Ioannidis JP: Impact of violations and deviations in Hardy-Weinberg equilibrium on postulated gene-disease associations. Am J Epidemiol 2006, 163:300–309.PubMedCrossRef 38. Ioannidis JP, Patsopoulos NA, Evangelou E: Uncertainty in heterogeneity estimates in meta-analyses. BMJ 2007, 335:914–916.PubMedCrossRef Competing interests The authors

do not have any potential competing interests. Authors’ contributions PQL, QAP, LXJ and MCJ conceived and designed the study, CZP, SJZ, WJR, ZLM, YS, QX, and LS participated in selecting study, extracting data, performing the statistical analysis and drafting Sitaxentan the manuscript. PQL has been involved in revising the manuscript critically for important intellectual content. All authors read and approved the final manuscript.”
“Background Lung cancer is the most common cancer and the leading cause of cancer deaths around the world [1]. Although prognosis of patients can be improved through effective treatment, the 5-year survival rate of patients with advanced lung cancer is only 10%-15% [2]. Non-small cell lung cancer (NSCLC) accounts for 70%-80% in lung cancer, and among them, lung adenocarcinoma (LAD) accounting for almost half of lung cancers, was one of the most common histologic subtype. Patients with LAD had rapid disease progression, and recurrence ratio was high even after surgery.